Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy
Reid W. Merryman(Harvard University), Heather A. Jacene(Brigham and Women's Hospital), Eleanor Taranto(Unknown), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Benjamin L. Lampson(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Gulrayz Ahmed(Medical College of Wisconsin), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Patrizia Mondello(WinnMed), Erin Jeter(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Matthew Chase(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Gabriela Spilberg(Brigham and Women's Hospital)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k